# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects

> **NCT02217917** · PHASE1 · COMPLETED · sponsor: **GlycoMimetics Incorporated** · enrollment: 27 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rivipansel
- **DRUG:** Placebo
- **DRUG:** Rivipansel
- **DRUG:** Rivipansel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02217917
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02217917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02217917, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02217917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*